Last $7.70 USD
Change Today 0.00 / 0.00%
Volume 0.0
GALTU On Other Exchanges
As of 8:10 PM 02/3/15 All times are local (Market data is delayed by at least 15 minutes).

galectin therapeutics - uts (GALTU) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/25/14 - $50.05
52 Week Low
02/3/15 - $7.70
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

galectin therapeutics - uts (GALTU) Related Bloomberg News

View More Bloomberg News

galectin therapeutics - uts (GALTU) Related Businessweek News

No Related Businessweek News Found

galectin therapeutics - uts (GALTU) Details

Galectin Therapeutics Inc., a development stage company, is engaged in the research and development of therapies for fibrotic disease and cancer. The company’s lead product candidates include GR-MD-02, a complex polysaccharide polymer for the treatment of liver fibrosis and fatty liver disease for which the company intends to initiate a Phase I clinical trial in patients with non-alcoholic steatohepatitis; and GM-CT-01, a linear polysaccharide polymer comprising mannose and galactose that is in a Phase I/II clinical trials in Europe as a combination with a tumor vaccine in patients with advanced melanoma, a skin cancer. Galectin Therapeutics Inc., through its collaborative joint venture, Galectin Sciences, LLC with SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

6 Employees
Last Reported Date: 03/21/14
Founded in 2000

galectin therapeutics - uts (GALTU) Top Compensated Officers

Chief Executive Officer, President, Chief Med...
Total Annual Compensation: $569.7K
Executive Chairman
Total Annual Compensation: $360.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $127.3K
Chief Operating Officer and Corporate Secreta...
Total Annual Compensation: $260.0K
Compensation as of Fiscal Year 2013.

galectin therapeutics - uts (GALTU) Key Developments

Galectin Therapeutics Announces Details of Design of its Phase 2 Program With GR-MD-02

Galectin Therapeutics announced details of the design of its Phase 2 program with GR-MD-02 in patients with advanced fatty liver disease, or nonalcoholic steatohepatitis (NASH) with cirrhosis. The program includes two clinical studies. The first is a multicenter, randomized, placebo-controlled, double-blind, parallel-group Phase 2 trial to evaluate the safety and efficacy of GR-MD-02 for the treatment of liver fibrosis and resultant portal hypertension in patients with NASH cirrhosis (the NASH-CX trial). This trial is expected to commence in the second quarter of 2015 with data readout expected in the fourth quarter of 2017. In addition, the Company will conduct a smaller trial of shorter duration in NASH patients with advanced fibrosis (the NASH-FX trial). The NASH-CX trial was designed with guidance from the U.S. Food and Drug Administration (FDA) received during an End-of-Phase 1 meeting. The NASH-CX trial will include 45 sites (and up to 60 sites, if necessary) in the U.S. and Canada and will enroll a total of 156 patients. It will be comprised of three parallel treatment arms of 52 patients each, with one arm receiving 8 mg/kg of GR-MD-02, the expected therapeutic dose, one arm receiving 2 mg/kg of GR-MD-02 and a third arm receiving placebo. Patients will receive a total of 26 infusions every other week for one year and will be evaluated to determine the change in the hepatic venous pressure gradient (HVPG) as compared with placebo. The FDA has indicated that HVPG may serve as a surrogate primary endpoint for NASH cirrhosis. HVPG will be correlated with secondary endpoints of fibrosis on liver biopsy as well as with measurement of liver stiffness (FibroScan®) and assessment of liver metabolism (13C-methacetin breath test, Exalenz), which are non-invasive measures of the liver that may be used in future studies. Galectin is finalizing a submission to the FDA by the end of February for a Special Protocol Assessment (SPA) to accept this trial, if positive, as one of the required trials to support approval of the drug candidate. The FDA has previously agreed to review this study protocol for acceptance under an SPA.

Galectin Therapeutics, Inc. Presents at RedChip Global Online CEO Conference, Jan-28-2015 11:30 AM

Galectin Therapeutics, Inc. Presents at RedChip Global Online CEO Conference, Jan-28-2015 11:30 AM.

Galectin Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Galectin Therapeutics, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported net loss applicable to common stock of $3,853,000 or $0.17 per basic and diluted share against $3,723,000 or $0.21 per basic and diluted share a year ago. Total operating loss was $3,477,000 against $3,545,000 a year ago. For the nine months, the company reported net loss applicable to common stock of $12,992,000 or $0.60 per basic and diluted share against $18,836,000 or $1.15 per basic and diluted share a year ago. Total operating loss was $11,696,000 against $9,300,000 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GALTU:US $7.70 USD 0.00

GALTU Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GALTU.
View Industry Companies

Industry Analysis


Industry Average

Valuation GALTU Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GALECTIN THERAPEUTICS - UTS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at